Pharmaceutical compositions comprising ((6bR,10aS)-1-(4-fluorophenyl)-4-(3-methyl-2,3,6b,9,10,10a-hexahydro-1H-pyrido[3′,4′:4,5]pyrrolo[1,2,3-de]quinoxalin-8(7H)-yl)butan-1-one or pharmaceutically acceptable salts thereof
The present invention provides pharmaceutical compositions comprising certain optionally substituted heterocycle fused gamma-carbolines of Formula 2J, as shown below, and as further defined herein:
1. A pharmaceutical composition comprising toluenesulfonic acid and the compound of Formula 2J:
or a pharmaceutically acceptable salt thereof,
wherein:
k is 1;
m is 1;
n is 1;
R 1 is 4-(4-fluorophenyl)-4-oxobutyl;
R 5 is H;
R 6a and R 6b are independently H;
R 7 , R 8 and R 9 are independently H;
R 10 is CH 3 ; and
X is —N—.
2. The pharmaceutical composition according to claim 1 , wherein the compound of Formula 2J is a free base of the compound of Formula 2J.
3. The pharmaceutical composition according to claim 1 , wherein the compound of Formula 2J is a pharmaceutically acceptable salt of the compound of Formula 2J.
4. The pharmaceutical composition according to claim 3 , wherein the pharmaceutically acceptable salt of the compound of Formula 2J is the toluenesulfonic acid addition salt.
5. The pharmaceutical composition according to claim 1 , wherein the pharmaceutical composition comprises the toluenesulfonic acid and the compound of Formula 2J in a stoichiometric ratio.
6. A method for antagonizing 5-hydroxytryptamine 2 receptors in a patient, comprising administering to the patient in need thereof an effective amount of the pharmaceutical composition according to claim 2 .
7. A method for antagonizing 5-hydroxytryptamine 2 receptors in a patient, comprising administering to the patient in need thereof an effective amount of the pharmaceutical composition according to claim 3 .
8. A method for antagonizing 5-hydroxytryptamine 2 receptors in a patient, comprising administering to the patient in need thereof an effective amount of the pharmaceutical composition according to claim 4 .
9. A method for modulating 5-hydroxytryptamine receptor 2A activity in a patient, comprising administering to the patient in need thereof an effective amount of the pharmaceutical composition according to claim 2 .
10. A method for modulating 5-hydroxytryptamine receptor 2A activity in a patient, comprising administering to the patient in need thereof an effective amount of the pharmaceutical composition according to claim 3 .
11. A method for modulating 5-hydroxytryptamine receptor 2A activity in a patient, comprising administering to the patient in need thereof an effective amount of the pharmaceutical composition according to claim 4 .
12. A pharmaceutical composition comprising a toluenesulfonic acid addition salt of the compound of Formula 2J:
wherein:
k is 1;
m is 1;
n is 1;
R 1 is 4-(4-fluorophenyl)-4-oxobutyl;
R 5 is H;
R 6a and R 6b are independently H;
R 7 , R 8 and R 9 are independently H;
R 10 is CH 3 ; and
X is —N—.